1009 Results

People

  1. Motzer
    Motzer
  2. O'Reilly
    O'Reilly
  3. Kris
    Kris
  4. Aghajanian
    Aghajanian
  5. Hudis
    Hudis
  6. Bajorin
    Bajorin
  7. Kelsen
    Kelsen
  8. Ginsberg
    Ginsberg
  9. Krug
    Krug
  10. Scher
    Scher

Groups

  1. Department of Medicine (716)
  2. Solid Tumor Oncology Division (483)
  3. Hematologic Malignancies, Division of (277)
  4. Center for Hematologic Malignancies (224)
  5. Survivorship Research (151)
  6. Genitourinary Oncology Service (136)
  7. Epidemiology and Biostatistics (119)
  8. Radiology, Department of (111)
  9. Biostatistics Service (109)
  10. GSK Faculty (104)
  1. "anemia"
Formats
  1. Journal Article (926)
  2. Review (42)
  3. Research Letter (15)
  4. Conference Paper (12)
  5. Editorial (4)
  6. Guidelines (3)
  7. Miscellaneous (3)
  8. Correspondence (2)
  9. Book Section (1)
  10. Meeting Abstract (1)
Groups
  1. Department of Medicine (716)
  2. Solid Tumor Oncology Division (483)
  3. Hematologic Malignancies, Division of (277)
  4. Center for Hematologic Malignancies (224)
  5. Survivorship Research (151)
  6. Genitourinary Oncology Service (136)

More Groups

People
  1. Robert Motzer (55)
  2. Eileen O'Reilly (35)
  3. Mark Kris (32)
  4. Carol Aghajanian (31)
  5. Clifford Hudis (31)
  6. Dean Bajorin (29)

More People

Years
  1. 2025 (41)
  2. 2024 (99)
  3. 2023 (56)
  4. 2022 (45)
  5. 2021 (25)
  6. 2020 (62)

More Years

Publications
  1. Journal of Clinical Oncology (69)
  2. Cancer (50)
  3. Clinical Cancer Research (49)
  4. Lancet Oncology (47)
  5. Gynecologic Oncology (34)
  6. Blood (29)

More Publications

Publishers
  1. Elsevier Inc. (147)
  2. Springer (90)
  3. Elsevier Science, Inc. (83)
  4. American Society of Clinical Oncology (74)
  5. Wiley Blackwell (65)
  6. Nature Publishing Group (61)

More Publishers

Results (1009)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
    Journal Article

    Fontana, E.; Rosen, E.; Lee, E. K.; Højgaard, M.; Mettu, N. B.; Lheureux, S.; Carneiro, B. A.; Cote, G. M.; Carter, L.; Plummer, R.; more...
    JNCI: Journal of the National Cancer Institute (2024)

    Fulltext@MSK | Save
  • Consideration of a novel surgical approach in the management of gastric adenocarcinoma and proximal polyposis syndrome
    Journal Article

    Judge, S. J.; Gearty, S. V.; Catchings, A.; Ranganathan, M.; Roehrl, M. H.; Vardhana, S. A.; Tang, L.; Stadler, Z. K.; Strong, V. E.
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14
    Journal Article

    Brown, J.; Miller, A.; Holman, L. L.; Backes, F.; Nagel, C.; Bender, D.; Miller, D. S.; Powell, M. A.; Westin, S. N.; Bonebrake, A.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: Characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
    Journal Article

    Rugo, H. S.; Oliveira, M.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Jhaveri, K. L.; Krivorotko, P.; Loibl, S.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer
    Journal Article

    Choudhury, N. J.; Lai, W. V.; Makhnin, A.; Heller, G.; Eng, J.; Li, B.; Preeshagul, I.; Santini, F. C.; Offin, M.; Ng, K.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
    Editorial

    Rodriguez-Otero, P.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; Vij, R.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: Subgroup analysis of the DESTINY-Breast04 study
    Journal Article

    Yamashita, T.; Sohn, J. H.; Tokunaga, E.; Niikura, N.; Park, Y. H.; Lee, K. S.; Chae, Y. S.; Xu, B.; Wang, X.; Im, S. A.; more...
    Breast Cancer (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
    Journal Article

    Wierda, W. G.; Shah, N. N.; Cheah, C. Y.; Lewis, D.; Hoffmann, M. S.; Coombs, C. C.; Lamanna, N.; Ma, S.; Jagadeesh, D.; Munir, T.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Phase II study of osimertinib in patients with epidermal growth factor receptor mutations: Results from the NCI-MATCH ECOG-ACRIN (EAY131) trial subprotocol E
    Journal Article

    Chen, M. F.; Song, Z.; Yu, H. A.; Sequist, L. V.; Lovly, C. M.; Mitchell, E. P.; Moscow, J. A.; Gray, R. J.; Wang, V.; McShane, L. M.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
    Journal Article

    Zelenetz, A. D.; Jurczak, W.; Ribrag, V.; Linton, K.; Collins, G. P.; Jiménez, J. L.; Bishton, M.; Dholaria, B.; Mengarelli, A.; Phillips, T. J.; more...
    HemaSphere (2024)

    Fulltext@MSK | Save